Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 29

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 29
---
 outcomes
in their investment results. Investors may experience a decline in the value of the shares they purchase from the Selling Shareholder
in this offering as a result of future sales made by us to the Selling Shareholder at prices lower than the prices such investors paid
for their shares in this offering. In addition, if we sell a substantial number of shares to the Selling Shareholder under the Purchase
Agreement, or if investors expect that we will do so, the actual sales of shares or the mere existence of our arrangements with the Selling
Shareholder may make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that
we might otherwise wish to effect such sales.

We may use proceeds from sales of ourDepositary Shares made pursuant to the Purchase Agreement in ways with which you may not agree or in ways which may not yield a significant return.

We will have broad discretion over the use of proceeds from sales of ourDepositary Shares made pursuant to the Purchase Agreement, including for any of the purposes described in the section entitled “ Use of Proceeds,” and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of the net proceeds, their ultimate use may vary substantially from their currently intended use. While we expect to use the net proceeds from this offering as set forth in “ Use of Proceeds,” we are not obligated to do so. The failure by us to apply these funds effectively could harm our business, and the net proceeds may be used for corporate purposes that do not increase our operating results or enhance the value of ourDepositary Shares.

Future resales and/or issuances of our Depositary Shares, including pursuant to this prospectus, or the perception that such sales may occur, may cause the market price of our shares to drop significantly.

On January 17, 2025, we entered
into the Purchase Agreement, pursuant to which the Selling Shareholder shall, subject to the restrictions and satisfaction of the conditions
in the Purchase Agreement, purchase from us up to an aggregate of $35.0 million of Depositary Shares, upon the terms and subject to the
conditions and limitations set forth in the Purchase Agreement.

The Depositary Shares that
may be issued under the Purchase Agreement may be sold, subject to the restrictions and satisfaction of the conditions in the Purchase
Agreement, by us to the Selling Shareholder at our discretion from time to